August 20, 2012
Abbott Japan on August 16 announced that it received approval on August 15 for Synagis Intramuscular Liquid Injection 50 mg and 100 mg (palivizumab), a new formulation of Synagis 50 mg and 100 mg for Intramuscular Injection, a humanized anti-respiratory...read more